Filtered By:
Therapy: Cancer Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 16008 results found since Jan 2013.

Health After Cancer: An Innovative Continuing Medical Education Course Integrating Cancer Survivorship Into Primary Care
Problem The transition from oncology care back to primary care after cancer therapy is challenging for cancer survivors who seek services that address the effect of their cancer history on their present health. Lack of knowledge about the health needs of cancer survivors is a barrier to incorporating survivorship care into primary care practice. Formal training in cancer survivorship is rarely included in medical education and presents an opportunity for intervention. Approach The authors developed (January 2019–March 2020) an online continuing medical education (CME) course for primary care physicians (PCPs) ...
Source: Academic Medicine - August 1, 2021 Category: Universities & Medical Training Tags: Innovation Reports Source Type: research

Q&A: Dr. John Mazziotta on the future of UCLA’s medical school and health system
Earlier in his life, Dr. John C. Mazziotta thought about becoming an architect. With a keen eye for form and function, he would apply his skills to the construction of great buildings. Instead, he chose medicine. Now, after more than 30 years at UCLA — where he has been chair of the department of neurology, an associate vice chancellor and executive vice dean, and founding director of the Ahmanson-Lovelace Brain Mapping Center — that style of visual thinking will serve him well in his new roles as vice chancellor for UCLA Health Sciences, dean of the David Geffen School of Medicine at UCLA and CEO of UCLA Health. “Th...
Source: UCLA Newsroom: Health Sciences - May 27, 2015 Category: Universities & Medical Training Source Type: news

Dental Practice Patterns for Oral Care in Medical Oncology Patients —a Survey-Based Assessment of Massachusetts Dentists
AbstractOral complications associated with cancer therapy lead to a significant deterioration of oral health and overall quality of life. The primary aim of this study was to assess dental practice patterns followed by dentists for oral care of medical oncology patients and to identify potential barriers to recommended care. A questionnaire-based survey was developed using the Qualtrics online platform. It was electronically distributed to all dentists within the Massachusetts Dental Society (MDS). Descriptive statistics were automatically computed by Qualtrics. A total of 363 responses (10.7%) were received. Dentists repo...
Source: Journal of Cancer Education - August 5, 2020 Category: Cancer & Oncology Source Type: research

Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes
AbstractPreclinical data provide evidence for synergism between ketogenic diets (KDs) and other oncological therapies. The aim of this systematic review was to summarize data from clinical studies that have tested KDs along with other treatments used within medical oncology. The PubMed database was searched using the key words"ketogenic" AND ("cancer" OR"glioblastoma"). A secondary search was conducted by screening the reference lists of relevant articles on this topic. Relevant studies for this review were defined as studies in which KDs were used complementary to surgery, radio-, chemo-, or ...
Source: Medical Oncology - January 10, 2020 Category: Cancer & Oncology Source Type: research

Sirtex Medical jumps on surging sales, profits for fiscal 2016
By Sarah Faulkner Shares in Sirtex Medical (ASX:SRX) closed up nearly 12% today after the Australian medical device company posted huge boosts to both the bottom and top lines. Sydney-based Sirtex Medical makes targeted liver cancer therapies using resin microspheres called SIR-sphere Y-90. Sirtex said profits were $40.8 million (A$53.6 million), or 70¢ (A92.2¢) per share, on sales of $177.2 million (A$232.5 million) for the fiscal year ended June 30. That represents profit growth of 32.8% compared with fiscal 2015, on sales growth of 32.0%. “This record profit result once again highlights the continued executi...
Source: Mass Device - August 24, 2016 Category: Medical Equipment Authors: MassDevice Tags: Drug-Device Combinations MassDevice Earnings Roundup Oncology Wall Street Beat Sirtex Medical Source Type: news

Skyline Medical to take 20% stake in Helomics, license Illumina ’ s gene sequencing tech
Fresh from its purchase of a 20% stake in joint venture partner Helomics, Skyline Medical (NSDQ:SKLN) said today that it inked a deal to license the MiSeqDx next-generation sequencing technology from Illumina (NSDQ:ILMN). Yesterday Minneapolis-based Skyline said it agreed to buy a lump of convertible shares representing 20% of Helomics, in exchange for 1.1 million newly issued SKLN shares, which combined with its existing right to convert a $500,000 loan would give it a 25% stake in the Pittsburgh-based precision diagnostics and contract research firm. Yesterday’s $1.14 closing price for Skyline stock would valu...
Source: Mass Device - December 20, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Diagnostics Genomics Molecular Diagnostics Mergers & Acquisitions Helomics Illumina Inc. Skyline Medical Source Type: news

Alpha Tau Medical raises $29m
Alpha Tau Medical said today it raised $29 million in a private funding round to help support its alpha radiation cancer therapy technology. The round was led by Israeli private equity firm Shavit Capital and joined by global equity crowdfunding platform OurCrowd.com and Medison Pharma venture capital arm Medison Ventures, the Israel-based company said. The round was also joined by Apax Partner founds Ronald Cohen and Alan Patricof, Alpha Tau said. “We are confident that Alpha Tau’s ground-breaking technology can be a game changer in the treatment of cancer. Importantly, under the guidance of an experienced m...
Source: Mass Device - September 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Funding Roundup Alpha Tau Medical Source Type: news

Highlights from the 59th scientific congress of the French Society of Medical Physics
The present focus issue of Physica Medica contains contributions presented in relation to the previous scientific congress of the French Society of Medical Physics (SFPM) that was organized in Rennes in the spring 2021. The SFPM congress, which occurs annually during 3  days, aims at bringing together physicists, dosimetrists, and other professionals involved in cancer therapy or in medical imaging to discuss current topics related to the three main fields of activity of the medical physicist i.e.
Source: Physica Medica: European Journal of Medical Physics - July 16, 2022 Category: General Medicine Authors: Marie-Claude Biston, Philippe Meyer, Ludovic Ferrer, Vincent Marchesi, Catherine Khamphan, Guillaume Bonniaud, Ana ïs Barateau, Joël Greffier, Caroline Lafond Tags: Editorial Source Type: research

Varian Medical releases new Velocity cancer imaging software
Varian Medical (NYSE:VAR) said today it launched an FDA-cleared version of its Velocity cancer imaging software, including a new Rapidsphere module. The newly launched Velocity 4.0’s Rapidsphere module is designed for Y90 selective internal radiation therapy dosimetry analysis and provides improved information on tumor responses and normal-tissue toxicity for patients undergoing SIRT, the Palo Alto, Calif.-based company said. The Velocity 4.0 software includes the company’s Velocity M3i multi-modality motion imaging component, the Velocity Aria sync component and the Velocity tumor & dose tracking componen...
Source: Mass Device - April 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Imaging Oncology Software / IT Varian Medical Systems Source Type: news

Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future.
CONCLUSION: The cost of cancer treatment in Kenya depends on the type of cancer, the modality, cost of medicines and the type of inpatient admission. The greatest contributors are currently the cost of medicines and inpatient admissions. This pilot study can inform future initiatives among the government as well as private and public insurance companies to increase available resources, and better allocate available resources, to more effectively treat patients with cancer in Kenya. We will be monitoring developments and conducting further research. PMID: 29860920 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - June 5, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Basket Trials for Intractable Cancer
This study has made a significant impact on clinical practice in cancer patients harboring the TRK translocation, and also illustrates the potential for future advancements in drug development and clinical trials of cancers harboring rare genomic alterations (50). Second, a basket trial may allow screening for potential efficacy across multiple tumor types in order to guide more traditional, disease-specific, follow-up studies. The goal of some basket trials is to obtain an overall assessment of the drug with pooled histologies; in such trials, subsequent analyses are straightforward, and are comparable to those in standa...
Source: Frontiers in Oncology - April 11, 2019 Category: Cancer & Oncology Source Type: research

SABCS15: 'Weeding the garden' with radiation while continuing breast cancer therapy
(University of Colorado Anschutz Medical Campus) An ongoing phase IIR/III clinical trial presented at the 2015 San Antonio Breast Cancer Symposium seeks to answer an important question in the treatment of early metastatic breast cancer: Should surgery or stereotactic body radiation be used to 'weed the garden' of a few sites of metastasis while continuing treatment that may still be controlling the initial tumor?
Source: EurekAlert! - Medicine and Health - December 8, 2015 Category: Global & Universal Source Type: news

Additional treatment with mistletoe extracts for patients with breast cancer compared to conventional cancer therapy alone - efficacy and safety, costs and cost-effectiveness, patients and social aspects, and ethical assessment
Ger Med Sci. 2022 Jul 14;20:Doc10. doi: 10.3205/000312. eCollection 2022.ABSTRACTBACKGROUND: Chemotherapy is often used in the treatment of breast cancer in women. Side effects such as diarrhea, fatigue, hair loss, fever or disturbances in blood formation impair the women's quality of life. An essential treatment goal of the accompanying mistletoe therapy (MT) used in complementary medicine is to improve the health-related quality of life during cancer therapy.AIM AND METHODS: The HTA report on which this article is based examines the medical efficacy and safety, costs and cost-effectiveness, patient and social aspects, an...
Source: GMS German Medical Science - September 26, 2022 Category: General Medicine Authors: Petra Schnell-Inderst Caroline Steigenberger Marcel Mertz Ilvie Otto Magdalena Flatscher-Th öni Uwe Siebert Source Type: research